Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "State-of-the-Art Modulating Hypoxia Signaling Pathway to Treat Human Diseases"
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 4830
Special Issue Editors
Interests: hypoxia inducible factors; stroke; neuroprotection; blood brain barrier; Vascular dementia; neuroinflammation; cerebrospinal fluid
Interests: regenerative medicine; tissue engineering; hypoxia; adult stem cells; pluripotent stem cells; tendon; cartilage; respiratory system; 3D culture
Interests: synthetic chemistry; 2-oxoglutarate oxygenase; oxygen sensing; hypoxia; epigenetics; demethylases; DNA repair; obesity; antibiotic biosynthesis; flavonoid and ethylene biosynthesis
Special Issue Information
Since the discovery of hypoxia inducible factors (HIF), the research on medical applications of HIF stabilizers/inhibitors has been growing at an exponential rate. The 2019 Nobel Prize in Physiology or Medicine went to the hypoxia researchers that discovered how cells sense and adapt to hypoxia. Low O2 tension (hypoxia) is mainly related to pathological situations, but it can also be a part of normal physiology. Hypoxia activates the hypoxia signaling pathway, which is predominately governed by HIF. HIF stabilization upregulates hundreds of human genes, which are related to metabolism, erythropoietin, angiogenesis, proliferation, and survival. On the other hand, HIF is engaged in the pathology of disease. Modulating the hypoxia signaling pathway, thus altering gene expression in diseases, can be used to treat these diseases, e.g., anemia, ischemic diseases, cancer. In this Special Issue, several of these aspects in hypoxia signaling modulation will be highlighted. We invite the submission of research papers that will consolidate our understanding in this area. Contributions to this Special Issue are invited in the form of reviews, research articles, communications, and concept papers.
Areas to be covered in this Special Issue may include but are not limited to:
- Hypoxia signaling in normal function;
- Hypoxia signaling in diseases;
- Hypoxia signaling in therapeutic targets;
- Development of hypoxia mimetic agents for clinical uses.
Dr. Ruoli Chen
Dr. Nicholas R. Forsyth
Prof. Christopher J. Schofield
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Hypoxia inducible facor